Anti-Inflammatory, Antioxidant, and Anti-Atherosclerotic Effects of Natural Supplements on Patients with FMF-Related AA Amyloidosis: A Non-Randomized 24-Week Open-Label Interventional Study.
AA amyloidosis
endothelial dysfunction
familial Mediterranean fever
inflammation
natural supplementation
oxidative stress
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
15 Jun 2022
15 Jun 2022
Historique:
received:
17
05
2022
revised:
09
06
2022
accepted:
10
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
We aimed to evaluate the effect of a combination of natural products on parameters related to inflammation, endothelial dysfunction, and oxidative stress in a cohort of familial Mediterranean fever (FMF) patients with Serum Amyloid A amyloidosis, in a non-randomized, 24-week open-label interventional study. Morinda citrifolia (anti-atherosclerotic-AAL), omega-3 (anti-inflammatory-AIC), and extract with Alaskan blueberry (antioxidant-AOL) were given to patients with FMF-related biopsy-proven AA amyloidosis. Patients were >18 years and had proteinuria (>3500 mg/day) but a normal estimated glomerular filtration rate (eGFR). Arterial flow-mediated dilatation (FMD), carotid intima media thickness (CIMT), and serum biomarkers asymmetric dimethylarginine (ADMA), high sensitivity C-reactive protein (hs-CRP), pentraxin (PTX3), malondialdehyde (MDA), Cu/Zn-superoxide dismutase (Cu/Zn-SOD), and glutathione peroxidase (GSH-Px) were studied at baseline and after 24 weeks of treatment. A total of 67 FMF-related amyloidosis patients (52 male (77.6%); median age 36 years (range 21−66)) were enrolled. At the end of a 24-week treatment period with AAL, AIC, and AOL combination therapy, ADMA, MDA, PTX3, hsCRP, cholesterol, and proteinuria were significantly decreased compared to baseline, while CuZn-SOD, GSH-Px, and FMD levels were significantly increased. Changes in inflammatory markers PTX3, and hsCRP were negatively correlated with FMD change, and positively correlated with decreases in proteinuria, ADMA, MDA, cholesterol, and CIMT. Treatment with AAL, AIC and AOL combination for 24 weeks were significantly associated with reduction in inflammatory markers, improved endothelial functions, and oxidative state. Efficient control of these three mechanisms can have long term cardiovascular and renal benefits for patients with AA amyloidosis.
Identifiants
pubmed: 35743929
pii: life12060896
doi: 10.3390/life12060896
pmc: PMC9228597
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Rheumatol. 2008 Jun;27(6):689-94
pubmed: 17926078
J Pharmacol Exp Ther. 2021 Feb;376(2):181-189
pubmed: 33214214
Gene. 2018 Jan 30;641:279-286
pubmed: 29080837
Rheumatology (Oxford). 2009 Aug;48(8):911-5
pubmed: 19478036
Calcif Tissue Int. 2016 Aug;99(2):121-30
pubmed: 27016924
Stroke. 1998 Feb;29(2):439-46
pubmed: 9472887
Circ Cardiovasc Imaging. 2014 Jul;7(4):619-28
pubmed: 24782115
J Clin Pathol. 1996 Jun;49(6):453-5
pubmed: 8763256
Rheumatology (Oxford). 2014 Nov;53(11):2002-8
pubmed: 24907154
Kidney Int. 1999 May;55(5):1899-911
pubmed: 10231453
Sci Rep. 2020 Oct 27;10(1):18374
pubmed: 33110219
J Clin Med. 2021 Aug 10;10(16):
pubmed: 34441808
Phytother Res. 2012 Oct;26(10):1427-40
pubmed: 22344842
J Rheumatol. 2016 Jan;43(1):154-60
pubmed: 26568587
Naunyn Schmiedebergs Arch Pharmacol. 2009 Dec;380(6):497-507
pubmed: 19894037
Ann N Y Acad Sci. 2007 Sep;1110:201-8
pubmed: 17911435
J Biol Chem. 1989 Dec 15;264(35):21340-5
pubmed: 2592379
J Chromatogr B Biomed Sci Appl. 1997 May 9;692(2):467-71
pubmed: 9188838
Lancet. 1992 Nov 7;340(8828):1111-5
pubmed: 1359209
Rheumatol Int. 2008 Oct;28(12):1211-6
pubmed: 18500463
J Agric Food Chem. 2005 Aug 24;53(17):6896-902
pubmed: 16104817
Am J Public Health. 2004 Mar;94(3):361-6
pubmed: 14998794
Kidney Int. 1994 Jan;45(1):1-9
pubmed: 8126996
Antioxid Redox Signal. 2021 Nov 20;35(15):1291-1307
pubmed: 33637016
Curr Diabetes Rev. 2007 Aug;3(3):198-203
pubmed: 18220672
Biochem Biophys Res Commun. 1997 Mar 17;232(2):497-502
pubmed: 9125209
Clin Rheumatol. 2007 Sep;26(9):1467-73
pubmed: 17242867
Ann Rheum Dis. 2014 Apr;73(4):662-7
pubmed: 23463692
Medicina (Kaunas). 2021 Oct 01;57(10):
pubmed: 34684086
Clin Biochem. 2001 Feb;34(1):65-70
pubmed: 11239518
N Engl J Med. 2002 May 2;346(18):1415-6; author reply 1415-6
pubmed: 11986423
J Agric Food Chem. 2018 Sep 5;66(35):9172-9188
pubmed: 30092632
J Rheumatol. 2008 Oct;35(10):2024-9
pubmed: 18785307
Ann Rheum Dis. 2014 Apr;73(4):704-9
pubmed: 23505237
World J Diabetes. 2014 Apr 15;5(2):176-97
pubmed: 24748931
Afr Health Sci. 2011 Aug;11 Suppl 1:S6-13
pubmed: 22135646
Hemodial Int. 2017 Jan;21(1):41-46
pubmed: 27378685
Kidney Int Rep. 2021 May 04;6(7):1775-1787
pubmed: 34307974
Nat Rev Nephrol. 2021 Mar;17(3):153-171
pubmed: 32963366
J Diabetes Complications. 2018 Mar;32(3):316-320
pubmed: 29398328
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
Mutat Res. 2004 Sep;567(1):1-61
pubmed: 15341901
Hum Genet. 1997 Dec;101(2):238-42
pubmed: 9402978
Ann Clin Biochem. 2012 May;49(Pt 3):229-41
pubmed: 22402917
J Membr Biol. 2011 Mar;240(1):55-62
pubmed: 21249347
Vasc Med. 2005 Jul;10 Suppl 1:S97-102
pubmed: 16444875
J Clin Epidemiol. 2017 Sep;89:4-11
pubmed: 28694121
Atherosclerosis. 2007 Dec;195(2):e161-7
pubmed: 17673217
BMJ. 2011 Jul 28;343:d4044
pubmed: 21798967
Toxicology. 2002 Aug 1;177(1):105-17
pubmed: 12126799
Free Radic Biol Med. 2008 Feb 1;44(3):386-93
pubmed: 17967429
Isr Med Assoc J. 2001 Jan;3(1):9-12
pubmed: 11344818
Sci Rep. 2020 Jun 2;10(1):9018
pubmed: 32488098
J Periodontol. 2018 Sep;89(9):1112-1120
pubmed: 29761911
Clin Rheumatol. 2017 Sep;36(9):2071-2077
pubmed: 28074304
Mod Rheumatol. 2012 Jun;22(3):431-7
pubmed: 21947799
BMC Nephrol. 2016 Nov 30;17(1):196
pubmed: 27899079
Arthritis Rheum. 2009 Oct 15;61(10):1447-53
pubmed: 19790133
Free Radic Biol Med. 2005 Jan 15;38(2):271-5
pubmed: 15607910
J Am Soc Nephrol. 2008 Feb;19(2):388-95
pubmed: 18199801